Blood: The best drug for isosome platelet hyperplasia, aspirin optimizes antiplatelet therapy

Ispeciallyanocal hyperplasia (ET) is characterized by abnormal macrocytocell production and an increased risk of blood clotsRecommended antithrombotic treatment options: small dose aspirin, once daily (od), but accelerated platelet generation may shorten the duration of platelet cyclooxidation (COX)-1 inhibitionresearchers conducted a multi-center double-blind trial to assess the effects of three aspirin programs to optimize platelet COX-1 inhibition while retaining COX-2-dependent blood vessel thrombosisrecruited 245 patients who took small doses of aspirin for a long time and were randomly divided into 1:1 aspirin 100 mg od group, two times a day (bid) or three times a day (tid) for 2 weeks of treatmenteffective biomarkers for serum thrombosin B2 (sTXB2), platelet COX-1 activity, and urethra cyclin metabolites (PGIM) excretion as the main evaluation indicators of efficacy and safety at random groupings and 2 weeks laterIn addition, urine TX metabolites (TXM) excretion, gastrointestinal tolerance and ET-related symptoms were also studiedassessable patients with bid and tid solutions showed a significant reduction in individual variability and a decrease in the median value of sTXB2: the od group, the bid group, or the tid group of sTXB2 were 19.3 ,9.7-40, 4 (2.1-6.7) and 2.5 .1.4-5.65? Three groups of urine PGIM is comparableIn both arm arms, the subjects' urine TXM was significantly reduced by 35%Patients in the tid group had a higher score of abdominal discomfort, the current recommended 75-100 od cardiovascular preventive aspirin program has a significant disadvantage in reducing platelet activation in the vast majority of ET patientsThe antiplatelet response of small doses of aspirin can be significantly improved by shortening the time between administrations to 12 hours, but no further reduction in the interval between administrations